Sarcosine, an isomer of L-alanine, has been proposed as a prostate cancer progression biomarker [1]. Both compounds are detected in urine, where the measured sarcosine/alanine ratio has been found to be higher in prostate biopsy-positive group versus controls. We present here preliminary evidence showing that urine samples spiked with sarcosine/alanine can be partially resolved in 3 min via tandem differential mobility analysis-mass spectrometry (DMA-MS). Based on the calibration curves obtained for two mobility peaks, we finally estimate their concentration ratio in urine
In the present thesis called "The modern analytical methods for detection of aminoacids asociated wi...
Multiple, complex molecular events characterize cancer development and progression(1,2). Deciphering...
Prostate cancer (PCa) is the most frequently diagnosed cancer and the second leading cause of cancer...
While sarcosine was recently identified as a potential urine biomarker for prostate cancer, further ...
Current prostate cancer (PCa) diagnosis based on prostate-specific antigen (PSA) has been gradually ...
The current prostate cancer (PCa) diagnosis, based on the blood prostate-specific antigen (PSA) leve...
Current prostate cancer (PCa) diagnosis based on prostate-specific antigen (PSA) has been gradually ...
Since sarcosine and d,l-alanine co-elute on reversed-phase high-performance liquid chromatography (H...
There has been recent interest in metabolite concentrations present in urine for noninvasive disease...
The aim of this pilot study is to evaluate sarcosine, uracil, and kynurenic acid in urine as potenti...
Shortly after sarcosine was delineated as a potential biomarker for prostate cancer in 2009, a varie...
Prostate cancer is the leading type of cancer diagnosed in men. Serum prostate-specific antigen leve...
Prostate carcinoma is one of the most frequent cancer diseases of maturated men. Diagnose of this ca...
Prostate cancer (CaP) is the most common type of tumour disease in men. Early diagnosis of cancer o...
Sarcosine, N-methyl glycine, could be used as a biomarker for the diagnosis of prostate cancer. It e...
In the present thesis called "The modern analytical methods for detection of aminoacids asociated wi...
Multiple, complex molecular events characterize cancer development and progression(1,2). Deciphering...
Prostate cancer (PCa) is the most frequently diagnosed cancer and the second leading cause of cancer...
While sarcosine was recently identified as a potential urine biomarker for prostate cancer, further ...
Current prostate cancer (PCa) diagnosis based on prostate-specific antigen (PSA) has been gradually ...
The current prostate cancer (PCa) diagnosis, based on the blood prostate-specific antigen (PSA) leve...
Current prostate cancer (PCa) diagnosis based on prostate-specific antigen (PSA) has been gradually ...
Since sarcosine and d,l-alanine co-elute on reversed-phase high-performance liquid chromatography (H...
There has been recent interest in metabolite concentrations present in urine for noninvasive disease...
The aim of this pilot study is to evaluate sarcosine, uracil, and kynurenic acid in urine as potenti...
Shortly after sarcosine was delineated as a potential biomarker for prostate cancer in 2009, a varie...
Prostate cancer is the leading type of cancer diagnosed in men. Serum prostate-specific antigen leve...
Prostate carcinoma is one of the most frequent cancer diseases of maturated men. Diagnose of this ca...
Prostate cancer (CaP) is the most common type of tumour disease in men. Early diagnosis of cancer o...
Sarcosine, N-methyl glycine, could be used as a biomarker for the diagnosis of prostate cancer. It e...
In the present thesis called "The modern analytical methods for detection of aminoacids asociated wi...
Multiple, complex molecular events characterize cancer development and progression(1,2). Deciphering...
Prostate cancer (PCa) is the most frequently diagnosed cancer and the second leading cause of cancer...